QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)
Close on Nov 18, 2026Market cap $656.27MP/E –Yield –
QuidelOrtho pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
QuidelOrtho's pe ratio was 346.7× on Jan 31, 2024, against 4.6× a year earlier. Over the last 3 years it ranged from 3.1× to 373.0×, with a median of 6.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Jan 31, 2024 | 346.7× | −26.3 |
| 2023 | Dec 29, 2023 | 373.0× | +368.4 |
| 2022 | Dec 30, 2022 | 4.6× | −2.6 |
| 2021 | Dec 31, 2021 | 7.3× | – |
See a number that looks wrong?